This message contains images. If you don't see images, click here to view.
Advertise in this news brief.




Text Version   RSS   Subscribe   Unsubscribe   Archive   Media Kit Jan. 8, 2014


 



Inflammation in biopsies may indicate lower prostate cancer risk
Urology Times
Signs of inflammation in a man’s prostate biopsy may indicate that he has a reduced risk of subsequently being diagnosed with prostate cancer in a future biopsy, according to the authors of a recently published study. The study’s investigators say that because of its predictive value, inflammation should be routinely reported in prostate biopsies. The association between inflammation and prostate cancer remains controversial. Some studies suggest that anti-inflammatory therapies reduce prostate cancer risk, while others have found that prostate inflammation is linked with a lower risk of cancer.
   Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE  


SPONSORED CONTENT


Lung cancer screening with CT scans urged for heavy smokers
The Boston Globe
Many heavy smokers and ex-smokers who recently quit should be screened annually for lung cancer with a computed tomography (CT) scan that uses a low dose of radiation, a national panel of prevention experts said recently. Some of these people now get routine chest X-rays, but the panel concluded that CT scans are better able to detect the tiniest lung cancers at an early, more curable stage. Current cigarette smokers ages 55 to 80 who have smoked the equivalent of a pack a day for 30 years or people who had those same smoking habits within the past 15 years should be screened, advised the U.S. Preventive Services Task Force, a group created by Congress.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Accreditation 101: Learning the Basics of CoC Accreditation and Standards
Commission on Cancer
Are you a new staff member just learning the ropes of CoC accreditation?
Is your cancer program considering CoC accreditation and you want to learn about the CoC standards?
Do you need a basic refresher on the CoC accreditation process and standards?

If you answered yes to any of these questions, then plan to attend Accreditation 101: Learning the Basics of CoC Accreditation and Standards in Austin, Texas, on Feb. 28, 2014. This is the only program developed and taught by CoC surveyors and staff who review the CoC Standards, provide practical information on how to achieve compliance, and discuss the important role you and your cancer team play throughout the continuum of cancer care. Get the information you need from the people involved in standard development and the survey process. For additional information, go to http://www.facs.org/cancer/schedules/accred101.html.

Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


PRODUCT SHOWCASE
  Special Offer for Readers of The CoC Brief — Practice Review
Are you concerned about diminishing reimbursements? Time to take action and give your practice a check up!
1) Take advantage of the complimentary Practice Analysis.
2) See how you can prepare for the Affordable care Act.
From production and reimbursement to coding and A/R, find out where you are and what you can do to take advantage of the changes in healthcare and to protect your practice.
 


Tests of low-risk HPV types fail to detect later cancer risk
Medscape
Testing for low-risk human papillomavirus (HPV) types should be excluded from cervical cancer screening because such tests fail to predict risk of developing cervical intraepithelial neoplasia (CIN) grade 3 or worse, as well as expose women to potential harm; in addition, they have no proven benefit for patients, according to two large studies. Both reports were published in the January 2014 issue of Obstetrics & Gynecology.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Exercise improves drug-associated joint pain in breast cancer survivors
Oncology Nurse Advisor
Breast cancer survivors taking aromatase inhibitors (AIs) such as anastrozole, letrozole, and exemestane experienced a reduction in joint pain if they exercised while on treatment. These results were presented at the 2013 San Antonio Breast Cancer Symposium, Dec. 10-14, 2013. Five years of AI use after surgery or other primary treatment is recommended for postmenopausal women diagnosed with stages 1 to 3 hormone receptor-positive breast cancers, which account for nearly 70 percent of all newly diagnosed breast cancer cases.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Changing immunosuppressants after transplant may reduce cancer risk
By Joy Burgess
Recent research has shown that the risk of cancer is much higher for individuals dealing with chronic kidney disease. While other studies have shown similar findings, this new research shows that patients with chronic kidney disease are also more likely to die from cancers — specifically, urinary tract cancer and breast cancer. Unfortunately, transplant researchers and physicians feel that immunosuppressant medications may be the cause of the increased risk of cancer.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


  FEATURED COMPANIES
Advertisement
Oncology OnTrack Supports Nurse Navigation
Oncology OnTrack is used to navigate patients with any cancer type from screening to diagnosis, treatment and survivorship, interfaces with other programs and supports accreditations.
Advertisement
Cancer Registry Impact

Ensure the highest quality oncology data reporting to help improve care and aid in decision making. Learn about Care Communications, Inc. Cancer Registry Services.


Clinicians who would prefer hospice for themselves are more likely to discuss it with patients
Oncology Nurse Advisor
Although the vast majority of physicians participating in a multiregional study indicated that they would personally enroll in hospice care if they received a terminal cancer diagnosis, less than one-third would discuss hospice care early in the course of treating a terminally ill patient with cancer. Recent research also identified factors that increased the likelihood that clinicians would choose hospice care for themselves and examines how their preferences relate to the timing of end-of-life care discussions with patients.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


National Cancer Data Base (NCDB) Call for Data
CoC Source
The official NCDB Call for Data announcement was sent to all programs in a special CoC Source on Oct. 15. The final date for initial submissions is Jan. 31 (midnight Central time), and corrections are due April 1 (midnight Central time). Click "read more" to view the data items required and layout specifications.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Induction chemotherapy fails in tongue cancer
Medscape
Induction chemotherapy (IC) is significantly inferior to primary surgery in patients with advanced tongue cancer, according to a comparative study published online Dec. 26, 2013, in JAMA Otolaryngology — Head and Neck Surgery. Referencing his team's failure as "complete" and "spectacular," lead investigator Dr. Douglas Chepeha from the University of Michigan Comprehensive Cancer Center in Ann Arbor told Medscape Medical News that patients should seek a good reconstructive team and undergo surgery to boost their chances of survival.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Researcher explores link between flame retardants and thyroid cancer
Medical Xpress
Flame retardants are everywhere around us. Governments require manufacturers to put these chemicals into our rugs, cars, furniture, curtains, mattresses and pillows, and even many items of apparel, especially for infants. It's hard to name an item that doesn't contain them. They're in cell phones and computers, stereos and televisions, coffee makers and microwaves. They are supposed to keep us safe by preventing products from bursting into flame and causing dangerous fires. But evidence is mounting that this prevention carries unforeseen costs for human health.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE
 
Advertisement

Advertisement



The CoC Brief

Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Samantha Emerson, Content Editor, 469.420.2669
Contribute news

Disclaimer: The CoC Brief is a digest of the most important news selected for the American College of Surgeons Commission on Cancer from thousands of sources by the editors of MultiBriefs, an independent organization that also manages and sells advertising. The Commission on Cancer does not endorse any of the advertised products and services. Opinions expressed in the articles are those of the author and not of the American College of Surgeons and the Commission on Cancer.


Be sure to add us to your address book or safe sender list so our emails get to your inbox. Learn how.

This edition of The CoC Brief was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here — it's free!

Recent issues

Jan. 2, 2014
Dec. 25, 2013
Dec. 18, 2013
Dec. 11, 2013






7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063